Insider Selling: CVS Health (NYSE:CVS) Director Sells $34,619,673.90 in Stock

CVS Health Corporation (NYSE:CVS) Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Larry Robbins also recently made the following trade(s):

• On Wednesday, May 20th, Larry Robbins sold 1,018,000 shares of CVS Health stock. The shares were sold at an average price of $93.82, for a total value of $95,508,760.00.
• On Tuesday, May 19th, Larry Robbins sold 1,983,538 shares of CVS Health stock. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10.

CVS Health Trading Down 0.1%

Shares of NYSE:CVS opened at $93.24 on Friday. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $98.43. The firm has a market capitalization of $118.97 billion, a price-to-earnings ratio of 41.08, a price-to-earnings-growth ratio of 0.91 and a beta of 0.60. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The business’s 50 day moving average price is $80.38 and its 200-day moving average price is $79.08.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter last year, the firm posted $2.25 EPS. The business’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities research analysts forecast that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is 117.18%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Bernstein reiterated an Outperform rating and raised its price target on CVS to $106, saying the company is well positioned for a Medicare Advantage turnaround. Bernstein Sees CVS Well Positioned for Medicare Advantage Turnaround
• Positive Sentiment: Glenview Capital said CVS has delivered about an 80% total return since May 2024, reinforcing confidence in the company’s operational turnaround and long-term investment case. Glenview Capital Issues Statement on CVS Health
• Neutral Sentiment: CVS announced a collaboration with America250 to support the nation’s 250th anniversary celebration, a brand-building move that is unlikely to have a major near-term effect on earnings. CVS Health Collaborates With America250 To Support the Nation’s 250th Anniversary Celebration
• Neutral Sentiment: Recent community and philanthropic announcements, including support for military families and senior housing, add to CVS’s public-facing story but are not likely to move the shares materially on their own. CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
• Negative Sentiment: Three major hospital systems, including affiliates tied to Mount Sinai, the University of Michigan, and the University of Kansas, sued CVS, alleging it siphoned about $250 million from the 340B drug program through reduced reimbursements. Hospitals sue CVS for allegedly siphoning $250M in 340B funds
• Negative Sentiment: Separate reports say hospital systems are expanding the 340B dispute, raising the risk of more litigation, settlement costs, and reputational pressure for CVS’s pharmacy-benefit operations. CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment
• Negative Sentiment: Director Larry Robbins disclosed several large stock sales over the past few days, including a roughly $187 million sale, which can weigh on investor sentiment even though he still owns a large stake. SEC Form 4 filing

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CVS. Mizuho increased their target price on CVS Health from $102.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft increased their price objective on CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. UBS Group increased their price objective on CVS Health from $97.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. TD Cowen increased their price objective on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Finally, The Goldman Sachs Group increased their price objective on CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.68.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. National Pension Service grew its holdings in CVS Health by 3.1% in the 3rd quarter. National Pension Service now owns 3,999,622 shares of the pharmacy operator’s stock valued at $301,532,000 after buying an additional 119,189 shares in the last quarter. Kingsview Wealth Management LLC grew its holdings in CVS Health by 316.2% in the 3rd quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after buying an additional 79,340 shares in the last quarter. AE Wealth Management LLC grew its holdings in CVS Health by 6.2% in the 3rd quarter. AE Wealth Management LLC now owns 257,204 shares of the pharmacy operator’s stock valued at $19,391,000 after buying an additional 14,983 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in CVS Health by 11.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,116 shares of the pharmacy operator’s stock valued at $16,971,000 after buying an additional 22,653 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in CVS Health by 186.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 396,368 shares of the pharmacy operator’s stock valued at $30,568,000 after buying an additional 258,050 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.